Digitally enabled therapies for adults with anxiety disorders: early value assessment
Closed for comments This consultation ended on at Request commenting lead permission
4 Further evidence
Evidence generation
4.1 Further evidence will be generated while the 6 recommended technologies are used in the NHS to address the immediate unmet need, with appropriate safety processes in place. The main outcomes prioritised by the committee for evidence generation are outlined in section 1.2.
4.2 The clinical experts stressed the importance of monitoring and managing patient safety during evidence generation. The companies advised that they have risk management systems in place, but that risk should be managed according to local care protocols. The committee concluded that using digitally enabled therapies in NHS Talking Therapies services could increase access to treatment and support, while ensuring patient safety through continued monitoring and review.
Research only
4.3 The committee concluded that there was not enough evidence to recommend the following technologies for early access in the NHS. They should only be used in research:
Cerina, Iona Mind, Minddistrict, Resony and Wysa for GAD or generalised anxiety symptoms
Minddistrict and SilverCloud programmes for health anxiety, OCD, panic disorder with or without agoraphobia, social anxiety disorder, and phobias.
4.4 Research should include well-designed and adequately powered studies with appropriate comparators in NHS Talking Therapies services. The main outcomes prioritised by the committee are outlined in section 1.2. Studies should address the evidence gaps outlined in this guidance and demonstrate the benefit of using these technologies for adults with anxiety disorders.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions